References
- Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAXTM and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385–97
- Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 2007;18:1109–17
- Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008;19: 1431–44
- Pluskiewicz W, Adamczyk P, Franek E, . Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX and nomogram by Nguyen et al. Conformity between methods and their clinical utility. Bone 2010;46:1661–7
- Sandu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV. Prognosis of fracture: evaluation of predictive accuracy of the FRAXTM algorithm and Gravan nomogram. Osteoporos Int 2010;21:863–71
- Tosteson ANA, Melton LJ III, Dawson-Hughes B, . Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008;19:437–47
- Dawson-Hughes B, Tosteson ANA, Melton III LJ, . Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008;19:449–58
- Lorenc RS, Głuszko P, Karczmarewicz E, Księżopolska-Orłowska K, Misiorowski W. [Recommendations for diagnostic and treatment procedures in osteoporosis. Reduction of fracture frequency by effective prevention and treatment]. Terapia 2007;9:5–33
- Johansson H, Kanis JA, McCloskey EV, . A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int 2011;22:453–61
- Lippuner K, Johansson H, Kanis JA, Rizzoli R. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 2009;20: 1131–40
- Lippuner K, Johansson H, Kanis JA, Rizzoli R. FRAX® assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 2010;21:381–9
- Ettinger B, Black DM, Dawson-Hughes B, Pressman AR, Melton LJ III. Updated fracture incidence rates for the US version of FRAX®. Osteoporos Int 2010;21:25–33
- Kanis JA, Johansson H, Oden A, . The effects of a FRAX® revision for the USA. Osteoporos Int 2010;21:35–40
- Pluskiewicz W, Drozdzowska B. How to assess osteoporosis management efficacy? Med Hypotheses 2010;75:674–84
- Bolland MJ, Siu AT, Mason BH, . 2010 Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 2011;26:420–7
- Van Geel TA, van den Bergh JP, Dinant GJ, Geusens PP. Individualizing fracture prediction. Maturitas 2010;65:143–6
- McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A. Clodronate reduces the incidence of fractures in community dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007;22:135–41
- Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®. Bone 2009;44:49–54
- Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®. Bone 2010;47:729–35
- Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. CPMP/EWP/552/95Rev.2, London: CHMP, 2006